FEZF1 and pachyonychia congenita: Recent research indicates that FEZF1-AS1 is significantly overexpressed and closely related to patient poor prognosis in a variety of malignancies, including nasopharyngeal carcinoma, hepatocellular carcinoma, cervical cancer, colorectal cancer, multiple myeloma, breast cancer, osteosarcoma, lung cancer, gastric cancer, and PC (181, 182).